News

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist
Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...
Novo Nordisk, U.S. biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash
Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...
Barchart on MSN10h
Stocks Mixed as US Consumer Sentiment Falls and Inflation Expectations Soar
The S&P 500 Index ($SPX) (SPY) today is up +0.04%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.05%, and the Nasdaq ...
Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...
Septerna, Inc.: Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...
PipelineReview.com18h
Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...